There were 19 men and 17 women with a median age of 58 years (range 26-67 years). Of 36 patients, 18 (50%) were diagnosed with diffuse large B cell lymphoma, 5 (14%) with MCL, 4 (11%) with follicular lymphoma, 3 (8%) with Hodgkin lymphoma, and 6 (17%) with other types. Disease status at harvest was complete response (CR) in 20 patients (56%) and non-CR in 16 patients (44%) (partial response, 14 patients; stable disease and progressive disease, 1 patient). Prior bone marrow involvement was determined in 16 patients (44%). Four patients (11%) underwent radiotherapy prior to harvest. PBSCs harvest regimens were ESHAP (etoposide, methylprednisolone, cytarabine, cisplatin) in 11 patients (31%); etoposide in 6 (17%); MA (methotrexate, cytarabine) in 5 (14%); DHAP (dexamethasone, cytarabine, cisplatin) in 4 (11%); G-CSF alone in 3 (8%); and other regimen in 7 patient (19%). The median number of regimens and chemotherapy cycles was 2 (range 1-4 cycles) and 9 (range 1-13 cycles), respectively, prior to PBSCs mobilization. Filgrastim was used in 14 patients (39%); lenograstim in 22 (61%). The median number of apheresis procedures was 2 (range 1-3 procedures). Median duration of G-CSF support was 6 days (range 4-10 days). PBSC harvest was performed at a median of 18 days (range 8-22 days) from the start of chemotherapy in 33 patients who underwent chemotherapy followed by G-CSF. The median number of CD34 positive cells collected on the first harvest day was 2.0 9 10 6 /kg (range 0.01-13.3 9 10 6 ). The median number of CD34 positive cells collected in total was 2.6 9 10 6 /kg (range 0.02-13.3 9 10 6 ). Number of patients with peripheral monocyte count [1,000/lL on the first harvest day was 27 (75%), and of these, 23 patients underwent successful harvest. Of 36 patients, 27 patients (75%) successfully harvested CD34 positive cells [2.0 9 10 6 /kg. Nine patients (25%) were poor mobilizers. In 33 patients who G-CSF granulocyte-colony stimulating factor, CR complete response, WBC white blood cell were using chemotherapy, CD34 positive cell yield was not associated with age C60 years, sex, prior bone marrow involvement, previous cycles of chemotherapy, previous radiotherapy, lenograstim or filgrastim, neutrophil count and platelet count in nadir as shown in Table 1 . Only a peripheral blood monocyte count [1,000/lL on the first harvest day was a predictor of a successful harvest (P = 0.020).
Of our study population, 75% of patients were successful in achieving adequate CD34 positive cells. Another report showed that prior fludarabine or alkylating agent therapy was associated with poor PBSC yields [2] . Moreover, a prior study suggested that a higher number of chemotherapy regimens has a negative impact on mobilization efficiency; in addition, the peripheral blood CD34positive cell count was also correlated with PBSC yields [3] . Kim et al. [4] reported that G-CSF injection 3 h prior to apheresis improved the efficacy of stem cells. As described above, various factors were reported to be associated with PBSC harvest. However, in our study, only peripheral blood monocyte count on the first harvest day predicts successful harvest as reported by Yang et al. [5] . Our study has several limitations, one of which is that it was an uncontrolled, retrospective, single-center study. In addition, different initial and harvest chemotherapy regimens were used. It is easy to measure peripheral blood monocyte count rather than peripheral CD34 positive cells counts, suggesting that it will become a reliable and simple indicator of PBSC harvest. However, further analysis is required in more cases.
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